Background

Historically, disease activity diminished during pregnancy in women with relapsing-remitting MS. Today, women with high disease activity are more likely to attempt pregnancy due to the disease control that new therapies offer. But disease activity during pregnancy in the modern day remains understudied.

Objectives

Describe disease activity in a modern pregnancy cohort, grouped by preconception disease-modifying therapy (DMT) class; determine the predictors of relapse during pregnancy.

Methods

Data were obtained from the MSBase Registry. Term/preterm pregnancies conceived from 2011-2019 were included. DMT were classed by low, moderate and high-efficacy. Annualized relapse rates (ARR) were calculated for each pregnancy trimester and 12 months either side. Predictors of relapse during pregnancy were determined using clustered logistic regression.

Results

We included 1640 pregnancies from 1452 women. DMT used in the year before conception were none (n=346), low (n=845), moderate (n=207) and high-efficacy (n=242). Most common DMT in each class was interferon-beta (n=597), fingolimod (n=147) and natalizumab (n=219) for low, moderate and high-efficacy respectively. Conception EDSS ≥2 was more common in higher efficacy DMT groups (high: 41.3%; moderate 28.5%; low 22.4%; none 20.2%). For low-efficacy and no DMT groups, ARR fell through pregnancy. ARR of the moderate-efficacy group increased in the 1^st pregnancy trimester (0.55 [95% CI 0.36-0.80] vs 0.14 [95% CI 0.10-0.21] on low-efficacy), then decreased to a trough in the third. Conversely, ARR steadily increased throughout pregnancy for those on high-efficacy DMT (3^rd trimester: 0.42 [95% CI 0.25-0.66] vs 0.12 [95% CI 0.07-0.19] on low-efficacy). Higher efficacy DMT groups were associated with higher ARR in the early postpartum period (high: 0.84 [95% CI 0.62-1.1]; moderate: 0.90 [95% CI 0.65-1.2]; low: 0.47 [95% CI 0.38-0.58]). Preconception use of high and moderate-efficacy DMT and higher preconception ARR were predictors of relapse in pregnancy. But, continuation of high-efficacy DMT into pregnancy was protective against relapse (odds ratio 0.80 [95% CI 0.68-0.94]). Age ≥35 years was associated with reduced odds of relapse.

Conclusions

Women with RRMS treated with moderate or high-efficacy DMT are at greater risk of relapse during pregnancy. Careful pregnancy management, and use of long-acting high-efficacy DMT preconception, or continuing natalizumab into pregnancy, may prevent relapse in pregnancy.

Background

Regional brain atrophy is a sensitive disability marker for MS patients. A previous study has shown that atrophy of the corpus callosum is an early marker for disease progression. However, the relationship between diffuse pathology in specific brain regions and the course of regional atrophy development remains poorly understood.

Objectives

To investigate quantitative T1 maps and entropy (amount of T1 inhomogeneity) in regional brain structures from diagnostic MRI (performed at disease onset) of MS patients and compare these findings with healthy controls (HC).

Methods

Fifty MS patients and 102 HC were examined on a 3T MRI scanner (MAGNETOM Skyra, Siemens Healthcare, Erlangen, Germany). The MRI protocol comprised 3D MP2RAGE, 3D MPRAGE, 3D FLAIR and 3D DIR. The calculation of T1 maps, brain structure segmentations and brain volume measurements were obtained from a single MP2RAGE scan. Lesion segmentation masks were obtained using the LeManPV prototype software (Siemens Healthcare, Erlangen, Germany). We evaluated T1 maps from normal-appearing white matter (excluding lesions) in the corpus callosum, the brain lobes, brainstem and cerebellum, as well as from normal-appearing gray matter (excluding lesions) in the thalami, basal ganglia, and cortical gray matter. We calculated median regional T1 relaxation times, T1 entropy and volume for the above-mentioned structures for the early-MS group and 50 age- and sex-matched HC subjects. Statistical comparison was performed using t-tests.

Results

The median T1 of the corpus callosum in the early MS group was 838 ms (SD 38.5), with entropy 8.42 (SD 0.24); compared to 810 ms (SD 25.2) and 8.23 (SD 0.13) in the HC group. Statistically significant differences were found in T1 times and entropy between the groups (p<0.001); volumes were, however, not statistically different. Smaller but also statistically significant differences in T1 maps and entropy were found for white matter of the brain lobes (p<0.001). Thalami volumes showed statistically significant differences between groups, but not median T1 times (MS group 1055 ms, SD 32.6 vs. HC 1049 ms, SD 21.2).

Conclusions

Pathology of the normal-appearing white matter in T1 relaxometry can already be detected at MS disease onset. In particular, corpus callosum T1 times were considerably higher at clinical onset of MS compared to HC. We hypothesize that early microstructural changes detected at disease onset lead to evolution of regional brain atrophy.

Background

The presence of infratentorial lesions early in the disease has been shown to have prognostic value for future disability in multiple sclerosis (MS). Quantitative imaging metrics such as T1 relaxometry might contribute to understanding the relationship between supratentorial (ST), infratentorial (IT), and spinal cord (SC) pathology.

Objectives

Our aim was to explore the association between ST, IT and SC pathology and microstructural tissue alterations assessed with T1 relaxometry in T2-hyperintense lesions as well as cerebral and cerebellar normal-appearing white matter (NAWM) in patients with recently diagnosed MS with- and without IT lesions.

Methods

Microstructural tissue alterations were assessed in 42 patients (mean age 33.6±8.0 years, median MS duration 0.2 years (0-2.3)) as deviations from normative T1 times, both obtained from the MP2RAGE sequence at 3T (MAGNETOM Skyra, Siemens Healthcare, Erlangen, Germany). The normative T1 values were voxel-wise modelled via a study-specific atlas based on spatially normalized data from 102 healthy individuals (21-59 years). Relationship between normalized IT volumes (mesencephalon, pons, medulla oblongata, cerebellum), SC volume, ST and IT lesion loads estimated by the Morphobox prototype, Scanview and LemanPV prototype, respectively and the deviations from normative T1 times expressed as z-score-derived metrics (volumes and means of voxels with z-scores above z-score 2 and below z-score 2) in lesions, cerebral and cerebellar NAWM were studied by partial correlations adjusted for age and brain lesion volume.

Results

Patients with IT lesions (n=23, 33.0±8.5 years) had larger lesion load, higher volumes of voxels with positive z-scores (> 2), higher mean of z-scores above 2 in lesions, and larger thalami than patients without IT lesions (n=19, 34.3±7.7 years). The remaining volumes and z-scores derived metrics did not differ between groups. Cerebellar volume correlated negatively with volume of voxels with negative z-scores (< 2) in cerebellar NAWM (partial correlation coefficient r=-.437, p=.005) only in patients with IT lesions. In patients without IT lesions, SC and pons volumes correlated negatively with volume of voxels with positive z-scores corresponding to areas of supratentorial T2 lesions (SC: r=-.669, p=.003, pons: r=-0.606, p=0.01).

Conclusions

Microstructural alterations identified as T1 z-scores relate differently to IT and SC volumes in MS patients with and without IT lesions. In the presence of IT lesions, changes in cerebellar NAWM (T1 shortening relative to healthy controls) are associated with lower cerebellar volume. In the absence of IT lesions, the association of cerebellar NAWM and cerebellar volume is not present. In patients without IT lesions, microstructural alterations in ST lesions (T1 prolongation) that might indicate the extent of tissue damage in lesions, are associated with lower pontine and SC volumes regardless of the T2 lesion load.

Background

Although conventional MRI acquisitions are of essence in the monitoring of MS, they show low specificity towards the microstructural nature of tissue alterations and exhibit rather low correlations with clinical metrics (“clinico-radiological paradox”). Conversely, recent advances in brain relaxometry allow characterizing microstructural alterations on a single-subject basis; the question yet remains whether such quantitative measurements can help bridging the gap between radiological and clinical findings.

Objectives

This study investigates whether automatically assessed alterations of T₁ relaxation times in brain lesions and normal-appearing white matter (NAWM) improve clinico–radiological correlations in early MS with respect to conventional measures.

Methods

102 healthy controls (65% female, [21-59] y/o) and 50 early-MS patients (76% female, [19-52] y/o) underwent MRI at 3T (MAGNETOM Skyra, Siemens Healthcare, Erlangen, Germany). The employed 3D protocol comprised MPRAGE, FLAIR (both used for lesion segmentation as in [Fartaria et al., 2017, MICCAI]), and MP2RAGE for T₁ mapping.

After the healthy controls’ data were spatially normalized into a study-specific template, reference T₁ values in healthy tissues were established by linear, voxel-wise modelling of the T₁ inter-subject variability [Piredda et al., MRM, 2020]. In the MS cohort, T₁ deviations from the established references were calculated as z-score maps.

Correlations between the EDSS and conventional measures, i.e. lesion volume and count, were compared against correlations with z-score-derived metrics in lesions and NAWM, namely the volume of voxels exceeding a given z-score threshold.

Results

Correlations between EDSS and lesion volume and count were found to be 0.23 and 0.18, respectively. Higher correlations were found between EDSS and the volume of voxels exceeding an absolute z-score threshold of 2, both in lesions and NAWM, with ρ=0.3 and ρ=0.33, respectively. Correlation further improved when considering only negative z-scores, ρ=0.36 for lesions and ρ=0.39 for NAWM. The highest correlation was found when considering absolute z-scores in the occipital lobe NAWM, ρ=0.47.

Conclusions

Microstructural alterations identified as T₁ z-scores were found to improve clinico–radiological correlation in comparison to conventional measures (lesion volume and count). Of notice, negative z-scores (i.e. abnormal T₁ shortening), which may be due to an increase in iron content, appear to be a potential predictor for the clinical state of an early MS patient.

Background

The dynamic of lesion activity and brain volume changes during the post-partum period in women with multiple sclerosis (MS) is not well understood.

Objectives

To describe the evolution of clinical and radiological disease activity, including brain volume loss during the pregnancy and post-partum period.

Methods

In this observational study of 62 women with relapsing-remitting MS, all 221 brain MRI scans were performed on the same 1.5-Tesla scanner. T2 lesion and brain volumes were analyzed by ScanView. MRI and clinical visits were scheduled at: late pre-pregnancy period: <24 and >6 months before pregnancy (56-measures); early pre-pregnancy period: <6 months before pregnancy (62-measures); early post-partum period: <3 months after delivery (62-measures); and late post-partum period: >12 and <24 months after delivery (41-measures). Differences in disease activity among time points were analyzed using the Wilcoxon signed-rank test.

Results

Eighteen (29.0%) women had a relapse during the year preceding pregnancy-onset, 9 (14.5%) women had a relapse during the pregnancy and 20 (32.3%) women had a relapse during the year following delivery. Disability status, as assessed by the expanded disability status scale (EDSS) remained unchanged during the follow-up. Women in early post-partum period (post) had higher T2 lesion volume (median: 0.94 ml vs 1.18 ml-post), greater annualized T2 lesion volume increase (0.0 ml vs 0.23 ml-post), lower brain parenchymal fraction (86.4% vs 85.7%-post) and greater annualized brain volume loss (-0.12% vs.-1.44%-post) compared with early pre-pregnancy period (all p>0.001). Forty-one women with available MRI data in late post-pregnancy (late-post) period had similar T2 lesion volume (1.18 ml vs 1.16 ml-late-post; p=0.14) and higher brain parenchymal fraction (85.6% vs. 86.0%-late-post; p=0.007) compared to early post-partum period.

Conclusions

The early post-partum period was associated with a transient increase in T2 lesion volume and accelerated brain volume loss compared to the pre-pregnancy period. In a proportion of women, newly accumulated T2 lesion volume and decreased brain parenchymal fraction did not return to its pre-pregnancy levels. These findings argue against any general protective effect of pregnancy on MS.

Background

Disease activity has been investigated in pregnant women with RRMS treated with low-efficacy or no therapy. How newer, more efficacious therapies affect relapse and disability progression risk after pregnancy remains understudied.

Objectives

To describe disease activity in a modern pregnancy cohort contrasted with historical cohorts. To determine the predictors of postpartum relapse and the predictors of six-month confirmed disability progression events in a contemporary pregnancy cohort.

Methods

Data were obtained from the MSBase Registry. Term/preterm pregnancies conceived from 2011-2019 (modern cohort) were compared with those conceived between 2005-2010 and pre-2005. Annualised relapse rates (ARR) were calculated for each pregnancy trimester and 12 months either side. Predictors of time-to-relapse postpartum (1^st 3 months) and time to 6-month confirmed disability progression event were determined with clustered Cox regression analyses. Breastfeeding duration and time to DMT reinitiation were modelled as time-varying covariates.

Results

We included 1640 pregnancies from 1452 women (modern cohort). Disease-modifying therapy (DMT) used in the year before conception included interferon-beta (n=597), natalizumab (n=219) and fingolimod (n=147). Continuation of DMT up to conception increased over time (31% pre-2005 vs 54% modern cohort). Preconception ARR decreased across epochs (pre-2005: 0·58 [95% CI 0·49-0·70]; 2005-2010: 0·40 [95% CI 0·36-0·45]; modern: 0·29 [95% CI 0·27-0·32]). In all epochs, ARR decreased during pregnancy to reach similar troughs in the 3^rd trimester, and rebounded in the 1^st 3-months postpartum. Preconception use of high-efficacy DMT predicted early postpartum relapse (hazard ratio (HR) 2.1 [1.4-3.1]); although those on no DMT were also at risk of postpartum relapse, relative to women on low-efficacy DMT (HR 2.7 [1.2-5.9]). Conception EDSS ≥2, higher preconception and in-pregnancy ARR were also risk factors. DMT reinitiation, particularly of high-efficacy DMT (HR 0.17 [0.07-0.38]), was protective against postpartum relapse. Women who breastfed were less likely to relapse (HR 0.63 [0.42-0.94]). 4.5% of modern pregnancies had confirmed disability progression after delivery. This was predicted by higher pregnancy and postpartum ARR, with postpartum ARR remaining independently predictive in multivariable analysis (HR 1.5 [1.2-2.0]).

Conclusions

The early postpartum period remains a period of vulnerability for disease rebound in women with MS in the modern era. Early DMT reinitiation, particularly with high-efficacy treatment, is protective against postpartum relapse. Confirmed disability progression events after pregnnacy are uncommon in the modern era. Relapse activity is the key driver of these events.